Chabiotech Co.,Ltd.
Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2002 and listed on KOSDAQ in 2005, Chabiotech is a biotech company built around cord blood banking, stem cell research, and cell therapy development. It also offers anti-aging services and consulting drawing on this expertise, while its subsidiaries run a pharmaceuticals, cosmetics, and cosmetic-ingredients product business alongside a global CDMO business and overseas medical network expansion. On a consolidated basis, 2025 revenue was split 58.65% from medical services such as overseas medical network expansion, 9.61% from product sales including pharmaceuticals and cosmetics, and 31.74% from other businesses including the global CDMO operation.
Products & technology
- Cord blood bankingCord blood storage service
- Stem cell research and cell therapy developmentStem cell research and cell therapy development
- Anti-aging services and consultingAnti-aging related service and consulting leveraging accumulated know-how
- Medical services (overseas medical network)Overseas medical network expansion and related services
- Product sales (pharmaceuticals/cosmetics/cosmetic ingredients)Sale of pharmaceuticals, cosmetics, and cosmetic ingredients
- Global CDMO businessGlobal CDMO business and other service businesses via subsidiaries
Clinical trials
data.go.kr14 MFDS clinical trial authorisations · 2012–2024 (Phase 1 6 · Phase 1/2a 4 · Bioequivalence 3 · Phase 2 1)
- Phase 1CordSTEM-ST2024-05-07
1 trial site
- Phase 1CordSTEM-ST2022-11-09
1 trial site
- Phase 1CBT1012020-09-08
1 trial site
- Phase 1/2aCordSTEM-DD2020-09-01
7 trial sites
- Phase 1Cordstem-CD Kit2016-09-13
1 trial site
- Phase 1/2aCordSTEM-DD2016-05-03
7 trial sites
- Phase 1CB-AC-022015-11-11
1 trial site
- Bioequivalence몬테오티에프구강붕해필름5밀리그램(몬테루카스트나트륨)2014-10-15
2 trial sites
- Bioequivalence몬테오티에프구강붕해필름10밀리그램(몬테루카스트나트륨)2014-10-15
2 trial sites
- Phase 1CordSTEM-ST2014-09-11
1 trial site
- Phase 2PLX-PAD 주사용 현탁액2013-11-11
8 trial sites
- Phase 1/2aMA09-hRPE2013-10-18
1 trial site
Show 2 more
- Bioequivalence아리피프라졸오티에프구강붕해필름 10mg(아리피프라졸)2013-03-12
2 trial sites
- Phase 1/2aMA09-hRPE2012-05-21
2 trial sites
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition